Share Name Share Symbol Market Type Share ISIN Share Description
Immupharma LSE:IMM London Ordinary Share GB0033711010 ORD 10P
  Price Change % Change Share Price Shares Traded Last Trade
  +5.90p +15.49% 44.00p 18,279,594 16:35:13
Bid Price Offer Price High Price Low Price Open Price
43.10p 43.40p 50.00p 37.10p 37.10p
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.2 -6.3 -4.5 - 61.37

Immupharma (IMM) Latest News (1)

More Immupharma News
Immupharma Takeover Rumours

Immupharma (IMM) Share Charts

1 Year Immupharma Chart

1 Year Immupharma Chart

1 Month Immupharma Chart

1 Month Immupharma Chart

Intraday Immupharma Chart

Intraday Immupharma Chart

Immupharma (IMM) Discussions and Chat

Immupharma Forums and Chat

Date Time Title Posts
21/4/201806:04IMMUPHARMA - IN FINAL PHASE 3 LUPUS TRIAL TARGETING BLOCKBUSTER ($1bn+) REVENUES28,635
17/4/201813:0750 Dollars2
17/4/201808:55ImmuPharma - Global Potential Blockbusters & Huge Potential Upside95
20/3/201814:30UK Investor Show-
27/2/201811:09The ned1

Add a New Thread

Immupharma (IMM) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2018-04-20 16:15:0043.60292,171127,374.08O
2018-04-20 16:06:2544.0033,00014,520.00O
2018-04-20 16:02:0844.59374,478166,985.66O
2018-04-20 16:02:0344.59458,029204,242.37O
2018-04-20 15:35:2644.001,224538.56O
View all Immupharma trades in real-time

Immupharma (IMM) Top Chat Posts

DateSubject
20/4/2018
09:20
Immupharma Daily Update: Immupharma is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker IMM. The last closing price for Immupharma was 38.10p.
Immupharma has a 4 week average price of 19p and a 12 week average price of 19p.
The 1 year high share price is 193p while the 1 year low share price is currently 19p.
There are currently 139,467,430 shares in issue and the average daily traded volume is 17,677,640 shares. The market capitalisation of Immupharma is £61,365,669.20.
19/4/2018
11:13
hamhamham1: Shares Logo Menu Shares News ImmuPharma crashes 85% as Phase III lupus trials flop 17 April 2018, 11:18 Shares in drug discovery company ImmuPharma (IMM:AIM) collapsed on Tuesday demonstrating just how risking early stage drug development really is. The company's lead drug Lupuzor failed to show meaningful statistical benefits over placebo in Phase III trials. Lupus is an autoimmune disease that affects millions, famously including American singer and actress Selena Gomez. This massive blow has wiped million of pounds off the company's market value as investors dump the stock. The share price has crashed 85% to 22.7p leaving the firm's market value at just £32m. The stunning scale of the sell-off is perhaps no surprise considering the £10m of fresh funding raised from investors as recently as January. That cash call was struck at 144p per share. In April 2017, we wrote about the blockbuster potential that had started to build among investors for Lupuzor. Those hopes look largely dashed now. ImmuPharma is far from alone at falling at clinical testing hurdles. Last year, Circassia (CIR) was forced to abandon its anti-allergy programme after its dust mite allergy study failed to show the treatment had a ‘significant effect’ compared to placebo. WHAT’S NEXT? ImmuPharma will undertake a review of the data and work with regulatory advisers to determine their next move. Talks are also ongoing with several large pharma companies. ‘Our initial reaction is to assume Lupuzor is no longer a meaningful candidate for marketing authorisation for the treatment of lupus and we now look to what would be a reasonable value for the business,’ comments Panmure Gordon’s Mike Mitchell. He argues for a £31m enterprise value, which strips out the anticipated £11m of net cash he estimates that the company will hold come year end on 31 December 2018. That implies a 22p share price. Deal now » Find out how to deal online from £1.50 Issue Date: 17 Apr 2018 Save Share Sign In or Subscribe to a Premium account to comment. Lisa-Marie Janes profile pic Lisa-Marie Janes Related news Weir makes splash with $1.29bn mining services deal, exposing itself even more to cyclical industry Market report: Cheers for Weir, downgrades for Debenhams Shares in cyber security and ID firm GB jump 12%, here’s why Hammerson listens to the market and walks away from Intu deal Rio Tinto defies major disruptions and avoids large downgrade to production guidance Shares in Animalcare slump on profit warning Dignity resurrected as deaths soar and more people opt for premium funerals than expected Asset manager Jupiter hit by clients withdrawing money and negative market conditions Market report: Hammerson up as M&A deal shelved Why asset manager Ashmore is in vogue today Shares Magazine Latest Issue Cover Latest Issue: 19 Apr 2018 Subscribe now @SharesMag @SharesMagDan: Today, 11:03 @wheeliedealer Hi WD - can you think of any stocks with a large net cash position relative to market cap? Thanks @SharesMagSteve: Today, 10:34 RT @SHARESmag: Weir makes splash with $1.29bn mining services deal, exposing itself even more to cyclical industry $WEIR hxxps://t.co/JMdr230; @SharesMagDan: Today, 10:17 RT @SHARESmag: Quality management is part of the success or failure of a company, which is why change at the top can often act as a catalys… < Previous Next > Terms And Conditions Investment Warning Privacy Disclaimers About Shares The Shares Team Contact Us
18/4/2018
11:46
hamhamham1: ImmuPharma crashes 85% as Phase III lupus trials flop 17 April 2018, 11:18 Shares in drug discovery company ImmuPharma (IMM:AIM) collapsed on Tuesday demonstrating just how risking early stage drug development really is. The company's lead drug Lupuzor failed to show meaningful statistical benefits over placebo in Phase III trials. Lupus is an autoimmune disease that affects millions, famously including American singer and actress Selena Gomez. This massive blow has wiped million of pounds off the company's market value as investors dump the stock. The share price has crashed 85% to 22.7p leaving the firm's market value at just £32m. The stunning scale of the sell-off is perhaps no surprise considering the £10m of fresh funding raised from investors as recently as January. That cash call was struck at 144p per share. In April 2017, we wrote about the blockbuster potential that had started to build among investors for Lupuzor. Those hopes look largely dashed now. ImmuPharma is far from alone at falling at clinical testing hurdles. Last year, Circassia (CIR) was forced to abandon its anti-allergy programme after its dust mite allergy study failed to show the treatment had a ‘significant effect’ compared to placebo. WHAT’S NEXT? ImmuPharma will undertake a review of the data and work with regulatory advisers to determine their next move. Talks are also ongoing with several large pharma companies. ‘Our initial reaction is to assume Lupuzor is no longer a meaningful candidate for marketing authorisation for the treatment of lupus and we now look to what would be a reasonable value for the business,’ comments Panmure Gordon’s Mike Mitchell. He argues for a £31m enterprise value, which strips out the anticipated £11m of net cash he estimates that the company will hold come year end on 31 December 2018. That implies a 22p share price.
11/4/2018
08:32
englishlongbow: 250k patients pa is conservative as its only 16% of developed market lupus sufferers and 5% of global. On a deal and PE of 20 at $25k pa per patient, it gives an IMM share price of £179. These figures are well known and use standard assimptions.
08/4/2018
21:37
fuji99: 14 patients (reported by the FDA) died during Benlysta trials. Those with severe Lupus developed suicidal behaviour. So if Lupuzor works, it will be the ONLY available safe medicine to treat Lupus sufferers. No need to underline the impact on IMM share price and the takeover battles to acquire it.
04/4/2018
12:13
squiresquire: HI Ham, Just saw your posts, no i havent got back in yet, we still have all of this week and all next week to go as i expect results to be RNSd on Monday 16th as if the lock is made on the 6th, then study implementers will need a few days before giving results to IMM, i would expect them to do so on the Friday, therefore IMM will be able to respond on the 16th at the earliest, thats my best guess. In view of the above i still think the market will thrash IMM share price around and still expect it to re-trace further. Basically the market is working the PIs to take on the II cast offs as they de-risk from huge positions already in very very substantial profits. Of course i may be wrong but i have plenty of lee way now to get back in at below my selling price yesterday.
03/4/2018
08:12
squiresquire: The charts are showing how we have moved up in the last few trading sessions. It has stopped at a major resistance level of circa 160p. The previous strong resistance of circa 130p was 'bounced around' for 8 weeks. From that level there were two major re-traces to below 100p, a drop of approx 30% During the 8 weeks from the end of January to the last week of March it retraced below 115p another 18 times. The above shows how much and how often this share re-traces. That is partly because of the very low liquidity of only approx 150 million shares in issue. It will keep doing this as this sharp movement is part of IMMs share DNA, a small sell creates a dis-proportionately large share price movement. If you care to look back at my posts, and i am not a 'serial' you will see i wrote well before the main re-traces we had below £1 that it would happen, and also wrote how it would happen, ie by how quickly. There were many criticisms of my posts from the 'boiler room' posters here paid to ramp up interest in the share price with utterly ludicrous forecasts on the share price. I have seen them in so many other shares that went on to crash or otherwise disappoint. However, NOT ONCE did any other poster on this thread post on BOTH occasions how a re-trace was about to happen. I am a holder here with a small amount of 15,000 shares at an average of 112p. I like the possibility of Phase 111 being a success, i truly hope it is, but no way am i following the advice of those posting every second to 'buy more, buy more' At the moment on the companies web site we have, as major holders and of interest to me: Aviva plc and subsidies 10,140,298 7.27% Landstead Investors 6,985,893 5.01% We also have the Private Investors who have come in since the last re-trace, or 'tree shake' sitting on a profit from the low of 92p, to £1.60. a profit of approx 60% in just a half dozen trading sessions. Last week it seemed as if a buyer had entered the market, but in my opinion the sellers are still there too, and as soon as the buyers stop another, rapid and radical 'treeshake' will take place. Aviva and Landstead above, have between them just over 17 million shares. (12.28) The vital question now is this, are BOTH Aviva AND Landstead going to keep ALL of their shares, or will they sell some to de-risk against a bad P111 result.. That is the real question at this stage because even the dumping of just 1,000,000, let alone 5 million in this share is, i think, going to cause a radical hit to the share price. But these institutions are not, like so many on this thread, gamblers, they are investors, and as such take profits on the way up, they donâ€482;t keep all for one big gamble and risk losing the house. Given the number of re-traces we saw on the last leg at £1.30, 18 in number below or around 110p with another two below 95p, this new level of 160p is once again, an utterly crucial price level. The previous re-traces from £1.30 were in some cases due to the big boys taking in profits, now the price is even higher their profits are even bigger. The 'boiler boys' are trying to cause panic buying, they keep saying ‘dont be forced outâ€482; or ‘buy nowâ€482; before its too late. The company has said as follows, ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company announces that it has been informed by Simbec-Orion, the contract research organisation conducting our Lupuzor(TM) pivotal Phase III trial study, that 'database lock' is expected on 6 April 2018, with top line results announced by mid-April 2018. Mid April, nearly two weeks away, during which time the institutions wanting to sell out even a small percentage of shares, have to do so and will, In my opinion, create more of the radical re-traces we have seen so often in the last weeks.
03/4/2018
07:27
squiresquire: The charts are showing how we have moved up in the last few trading sessions. It has stopped at a major resistance level of circa 160p. The previous strong resistance of circa 130p was 'bounced around' for 8 weeks. From that level there were two major re-traces to below 100p, a drop of approx 30% During the 8 weeks from the end of January to the last week of March it retraced below 115p another 18 times. The above shows how much and how often this share re-traces. That is partly because of the very low liquidity of only approx 150 million shares in issue. It will keep doing this as this sharp movement is part of IMMs share DNA, a small sell creates a dis-proportionately large share price movement. If you care to look back at my posts, and i am not a 'serial' you will see i wrote well before the main re-traces we had below £1 that it would happen, and also wrote how it would happen, ie by how quickly. There were many criticisms of my posts from the 'boiler room' posters here paid to ramp up interest in the share price with utterly ludicrous forecasts on the share price. I have seen them in so many other shares that went on to crash or otherwise disappoint. However, NOT ONCE did any other poster on this thread post on BOTH occasions how a re-trace was about to happen. I am a holder here with a small amount of 15,000 shares at an average of 112p. I like the possibility of Phase 111 being a success, i truly hope it is, but no way am i following the advice of those posting every second to 'buy more, buy more' At the moment on the companies web site we have, as major holders and of interest to me: Aviva plc and subsidies 10,140,298 7.27% Landstead Investors 6,985,893 5.01% We also have the Private Investors who have come in since the last re-trace, or 'tree shake' sitting on a profit from the low of 92p, to £1.60. a profit of approx 60% in just a half dozen trading sessions. Last week it seemed as if a buyer had entered the market, but in my opinion the sellers are still there too, and as soon as the buyers stop another, rapid and radical 'treeshake' will take place. Aviva and Landstead above, have between them just over 17 million shares. (12.28) The vital question now is this, are BOTH Aviva AND Landstead going to keep ALL of their shares, or will they sell some to de-risk against a bad P111 result.. That is the real question at this stage because even the dumping of just 1,000,000, let alone 5 million in this share is, i think, going to cause a radical hit to the share price. But these institutions are not, like so many on this thread, gamblers, they are investors, and as such take profits on the way up, they donâ€482;t keep all for one big gamble and risk losing the house. Given the number of re-traces we saw on the last leg at £1.30, 18 in number below or around 110p with another two below 95p, this new level of 160p is once again, an utterly crucial price level. The previous re-traces from £1.30 were in some cases due to the big boys taking in profits, now the price is even higher their profits are even bigger. The 'boiler boys' are trying to cause panic buying, they keep saying 'dont be forced out' or 'buy now' before its too late. The company has said as follows, ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company announces that it has been informed by Simbec-Orion, the contract research organisation conducting our Lupuzor(TM) pivotal Phase III trial study, that 'database lock' is expected on 6 April 2018, with top line results announced by mid-April 2018. Mid April, nearly two weeks away, during which time the institutions wanting to sell out even a small percentage of shares, have to do so and will, In my opinion, create more of the radical re-traces we have seen so often in the last weeks.
02/4/2018
15:56
squiresquire: The charts are showing how we have moved up in the last few trading sessions. It has stopped at a major resistance level of circa 160p. The previous strong resistance of circa 130p was 'bounced around' for 8 weeks. From that level there were two major re-traces to below 100p, a drop of approx 30% During the 8 weeks from the end of January to the last week of March it retraced below 115p another 18 times. The above shows how much and how often this share re-traces. That is partly because of the very low liquidity of only approx 150 million shares in issue. It will keep doing this as this sharp movement is part of IMMs share DNA, a small sell creates a dis-proportionately large share price movement. If you care to look back at my posts, and i am not a 'serial' you will see i wrote well before the main re-traces we had below £1 that it would happen, and also wrote how it would happen, ie by how quickly. There were many criticisms of my posts from the 'boiler room' posters here paid to ramp up interest in the share price with utterly ludicrous forecasts on the share price. I have seen them in so many other shares that went on to crash or otherwise disappoint. However, NOT ONCE did any other poster on this thread post on BOTH occasions how a re-trace was about to happen. I am a holder here with a small amount of 15,000 shares at an average of 112p. I like the possibility of Phase 111 being a success, i truly hope it is, but no way am i following the advice of those posting every second to 'buy more, buy more' At the moment on the companies web site we have, as major holders and of interest to me: Aviva plc and subsidies 10,140,298 7.27% Landstead Investors 6,985,893 5.01% We also have the Private Investors who have come in since the last re-trace, or 'tree shake' sitting on a profit from the low of 92p, to £1.60. a profit of approx 60% in just a half dozen trading sessions. Last week it seemed as if a buyer had entered the market, but in my opinion the sellers are still there too, and as soon as the buyers stop another, rapid and radical 'treeshake' will take place. Aviva and Landstead above, have between them just over 17 million shares. (12.28) The vital question now is this, are BOTH Aviva AND Landstead going to keep ALL of their shares, or will they sell some to de-risk against a bad P111 result.. That is the real question at this stage because even the dumping of just 1,000,000, let alone 5 million in this share is, i think, going to cause a radical hit to the share price. But these institutions are not, like so many on this thread, gamblers, they are investors, and as such take profits on the way up, they don’t keep all for one big gamble and risk losing the house. Given the number of re-traces we saw on the last leg at £1.30, 18 in number below or around 110p with another two below 95p, this new level of 160p is once again, an utterly crucial price level. The previous re-traces from £1.30 were in some cases due to the big boys taking in profits, now the price is even higher their profits are even bigger. The 'boiler boys' are trying to cause panic buying, they keep saying ‘dont be forced out’ or ‘buy now’ before its too late. The company has said as follows, ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company announces that it has been informed by Simbec-Orion, the contract research organisation conducting our Lupuzor(TM) pivotal Phase III trial study, that 'database lock' is expected on 6 April 2018, with top line results announced by mid-April 2018. Mid April, nearly two weeks away, during which time the institutions wanting to sell out even a small percentage of shares, have to do so and will, In my opinion, create more of the radical re-traces we have seen so often in the last weeks.
31/3/2018
09:32
njb67: mia You are right it will be considered and is a definite upside. The key issue from a valuation perspective is the timing of the revenues that would be generated. If it added an extra $1bn revenue in 2019, then the share price would rocket. If it was adding the same $1bn in 2024, then the value of these additional revenues today and impact on the share price would be much less. Time preference of money (we value an investment that will give us a return today much higher than one that gives us a return in five years) and risk need to be taken into account when valuing companies. While a positive P3 Lupus result would be a positive for the broader platform, the value of any future indications will be impacted by a range of factors: whether they too can generate positive clinical trial results too (not certain but risk reduced), how well they compare against existing treatments (we have a low bar in Lupus), how far into the future will we generate revenues, the value of the markets we are entering, where the product would be used in the patient pathway (restricted, widely used etc.) and so on. This is why I view £12/share as top end of what I think is possible in 2018 for IMM. I could be wrong. In five years time, assuming a successful Lupuzor launch for Lupus, and the next wave of indications launched or about to hit the market, then the share price could be considerably higher. But you are only going to get partial value for the pipeline in 2018. It is too far away revenue wise to contribute significantly to the current share price
30/3/2018
15:49
andrbea: One chap said if it hits £100 a share, i'll buy an island Well, on reading post 22004 (and that theoretical price of £358/share) I make that 3 islands' worth... LOL... Good luck everyone. top tips 29 Mar '18 - 16:23 - 22004 of 22079 0 2 2 culford --- refer below: Assuming: - Global lupus sufferers = 5 million (and growing) - Developed market lupus sufferers (US, Europe, Japan, SE Asia) = 1.5 million (and growing) and some sources including Imupharma suggest 1.5 million in the US alone. Thus: - 250,000 Lupuzor lupus patients at $25k pa = $6.25 billion pa revenue i.e. 5% of Global lupus sufferers, or 16.66% of developed markets sufferers. -- Sales $6.25 billion pa (above), 30% royalty to Immupharma + $200 million pa licensing fee to Immupharma; gives $1.875 billion + $200 m = $2.075 billion pa revenues to Immupharma. 96%+ gross margin, say $1.57 billion pa net (after gross margin & tax, etc), on PE ratio of 20 = $31.4 billion market capitalisation for Immupharma = Approx Immupharma share price £179. - 500,000 Lupuzor lupus patients (double above) at $25k pa = $12.5 billion pa revenue i.e. 10% of Global lupus sufferers, or 33.33% of developed markets sufferers. = Approx Immupharma share price £358.
Immupharma share price data is direct from the London Stock Exchange
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:42 V: D:20180421 06:12:20